Compositions and methods for treating ceacam positive cancers

An immune cell comprising:

• a. a first receptor, comprising an extracellular ligand binding domain specific to CEA cell adhesion molecule 5 (CEA);
• and
• b. a second receptor, comprising an extracellular ligand binding domain specific to HLA-A*02,
• wherein the first receptor is an activator receptor responsive to CEA;
• and wherein the second receptor is an inhibitory receptor responsive to HLA-A*02;
• wherein the extracellular ligand binding domain of the first receptor comprises a variable heavy (VH) portion comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2, and CDR-H3 of SEQ ID NOs:
• 55, 56, and 57, respectively, and a variable light (VL) portion comprising CDRs CDR-L1, CDR-L2, and CDR-L3 of SEQ ID NOs:
• 59, 61, and 63, respectively;
• and
• wherein the extracellular ligand binding domain of the second receptor comprises a VH portion comprising CDRs CDR-H1, CDR-H2, and CDR-H3 of SEQ ID NOs:
• 106, 107, and 108, respectively, and a VL portion comprising CDRs CDR-L1, CDR-L2, and CDR-L3 of SEQ ID NOs:
• 103, 104, and 105, respectively.